EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisationAccess, MPE15 December 2023
Sign up for the MPE webinar on ASH 2023 myeloma and AL amyloidosis highlightsAL amyloidosis, Conferences, MPE, Myeloma9 December 2023
The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myelomaAccess, Myeloma8 December 2023
MPE launches a report focused on the impact of AL amyloidosis in quality of lifeAL amyloidosis, MPE21 November 2023
ESMO 2023 | Patient Advocacy Track highlights challenges in access, caregiver support and digitalisationConferences, MPE27 October 2023
MPE launches European Amyloidosis Diagnosis Pathway to promote early detection of the rare diseaseAccess, AL amyloidosis26 October 2023
MPE to present at European Society for Medical Oncology (ESMO) Annual Congress 2023Conferences, MPE17 October 2023
EMA CHMP gives positive recommendation to elranatamab for the treatment of relapsed or refractory myelomaAccess, MPE, Myeloma13 October 2023
